Scholarlink

Objective <p>This observational clinical study aimed to evaluate the renal outcomes associated with dapagliflozin (sodium–glucose cotransporter-2, SGLT2) inhibitor, in hospitalized patients with type-2 diabetes mellitus (T2DM), with a focus on renal function improvement in a Pragmatic inpatient hospital Setting.</p> Methodology <p>Of 340 hospitalized patients screened in the current observational study, 113 met the inclusion criteria. Demographic characteristics and key laboratory parameters related to renal and metabolic function were collected and analysed using SPSS version 20.0. Descriptive and inferential statistics were applied to assess dapagliflozin’s impact on renal outcomes.</p> Results <p>Among the 113 participants (63 men and 50 women), treatment with dapagliflozin was associated with significant improvement in renal function indices and glycaemic markers. Mean eGFR rose from 60.25 ± 23.21 at baseline to 83.01 ± 21.93 by the second follow-up (<i>p</i> &lt; 0.001). UACR dropped significantly from 250.35 ± 83.46 to 137.96 ± 106.82, with more patients achieving normoalbuminuria (UACR &lt; 30&#xa0;mg/g, <i>p</i> &lt; 0.001). Serum creatinine decreased from 1.798 ± 0.862 to 1.222 ± 0.228 (<i>p</i> &lt; 0.001). BUN levels steadily declined from 35.57 ± 14.853&#xa0;mg/dL to 25.16 ± 9.093 (<i>p</i> &lt; 0.001). These findings suggest a positive correlation between dapagliflozin treatment and renal recovery in the inpatient clinical setting.</p> Conclusions <p>Dapagliflozin treatment significantly enhanced renal function in hyperglycaemic patients with type 2 diabetes and concurrent renal impairment. The current findings support its potential therapeutic value for hospitalized, high-risk patients with T2DM and renal dysfunction.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Positive Renal Outcomes Associated with Dapagliflozin Treatment in Hospitalized Patients with Type-2-Diabetes Mellitus: "An Observational Clinical Study in a Pragmatic Hospital Setting"

  • 期刊论文

  • 发表日期：

    2026年4月27日

查看全文
  • Hemalatha Selvaraj,
  • Dawn V. J,
  • Muralikrishnan Dhanasekaran

摘要

Objective

This observational clinical study aimed to evaluate the renal outcomes associated with dapagliflozin (sodium–glucose cotransporter-2, SGLT2) inhibitor, in hospitalized patients with type-2 diabetes mellitus (T2DM), with a focus on renal function improvement in a Pragmatic inpatient hospital Setting.

Methodology

Of 340 hospitalized patients screened in the current observational study, 113 met the inclusion criteria. Demographic characteristics and key laboratory parameters related to renal and metabolic function were collected and analysed using SPSS version 20.0. Descriptive and inferential statistics were applied to assess dapagliflozin’s impact on renal outcomes.

Results

Among the 113 participants (63 men and 50 women), treatment with dapagliflozin was associated with significant improvement in renal function indices and glycaemic markers. Mean eGFR rose from 60.25 ± 23.21 at baseline to 83.01 ± 21.93 by the second follow-up (p < 0.001). UACR dropped significantly from 250.35 ± 83.46 to 137.96 ± 106.82, with more patients achieving normoalbuminuria (UACR < 30 mg/g, p < 0.001). Serum creatinine decreased from 1.798 ± 0.862 to 1.222 ± 0.228 (p < 0.001). BUN levels steadily declined from 35.57 ± 14.853 mg/dL to 25.16 ± 9.093 (p < 0.001). These findings suggest a positive correlation between dapagliflozin treatment and renal recovery in the inpatient clinical setting.

Conclusions

Dapagliflozin treatment significantly enhanced renal function in hyperglycaemic patients with type 2 diabetes and concurrent renal impairment. The current findings support its potential therapeutic value for hospitalized, high-risk patients with T2DM and renal dysfunction.